Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides

• US 7,138,376 B2
• Filed: 09/30/2002
• Issued: 11/21/2006
• Est. Priority Date: 09/28/2001
• Status: Expired due to Term

• Current Assignee: Centre National De La Recherche Scientifique, Idenix Pharmaceuticals (Merck & Co., Inc.), Universite Montpellier II
• Original Assignee: Centre National De La Recherche Scientifique, Idenix Pharmaceuticals (Merck & Co., Inc.)
• Inventors: Sommadossi, Jean-Pierre, Gosselin, Gilles, Imbach, Jean-Louis
• Primary Examiner(s): Jiang, Shaojia Anna
• Assistant Examiner(s): Khare, Devesh
• Application Number:
  US10/261,244
• Publication Number:
  US 20040006007A1
• Time in Patent Office: 1,513 Days
• Field of Search: 514/43, 514/18, 514/422, 514/894, 514/2, 514/12, 514/312, 514/314, 514/21, 514/269, 514/339, 514/370, 514/42, 514/423, 514/425, 536/23.1, 536 23- 72, 536/23.4, 536/24.5, 536/24.32, 435/5, 435/6, 435/671, 424/228.1, 424/85.4, 424/85.7, 546/153, 546/171, 546/276.4, 548/523, 548/517, 544/283
• US Class Current: 514/43
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: C07H 19/056 Triazole or tetrazole radicals
• CPC Class Codes: C07H 19/06 Pyrimidine radicals
• CPC Class Codes: C07H 19/16 Purine radicals
• CPC Class Codes: C07J 1/00 Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
• CPC Class Codes: C07K 9/00 Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof

Abstract

A compound, method and composition for treating a host infected with a hepatitis C viral comprising administering an effective hepatitis C treatment amount of a described 4′-disubstituted nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

Claims

1. A compound of Formula I:

17. The compound as described in any of the preceding claims 1–

8, wherein the said compound is in the form of a dosage unit.

18. The compound as described in claim 17, wherein the dosage unit contains 10 to 1500 mg of said compound.

19. The compound as described in claim 17 or 18, wherein said dosage unit is a tablet or capsule.

2. A compound of Formula II:

3. A compound of Formula III, IV or V, or a pharmaceutically acceptable salt or prodrug thereof, is provided:

20. A compound as in claims 3, 4, 5, 6, 7, or 8, in which the purine or pyrimidine base is selected from the group consisting of

21. A compound as in claims 3, 4, 5, 6, 7, or 8, in which the purine or pyrimidine base is selected from the group consisting of:

22. A compound as in claims 3, 4, 5, 6, 7, or 8, in which the purine or pyrimidine base is selected from the group consiting of:

4. A compound of Formula III, IV or V, or a pharmaceutically acceptable salt or prodrug thereof, is provided:

5. A compound of Formula III, IV or V, or a pharmaceutically acceptable salt or prodrug thereof, is provided:

6. A compound of Formula III, IV or V, or a pharmaceutically acceptable salt or prodrug thereof, is provided:

7. A compound of Formula IV, or its pharmaceutically acceptable salt or prodrug, is provided:

8. A compound of Formula VI, or a pharmaceutically acceptable salt or prodrug thereof:

9. A pharmaceutical composition for the treatment of a hepatitis C virus in a host, comprising an effective amount of a compound of Formula I:

10. A pharmaceutical composition for the treatment of a hepatitis C virus in a host, comprising an effective amount of a compound of Formula II:

11. A pharmaceutical composition for the treatment of a hepatitis C virus in a host, comprising an effective amount of a compound selected from Formulas III, IV and V, or a pharmaceutically acceptable salt or prodrug thereof, is provided:

12. A pharmaceutical composition for the treatment of a hepatitis C virus in a host, comprising an effective amount of a compound of Formula VI, or a pharmaceutically acceptable salt or prodrug thereof:

23. The pharmaceutical composition as described in any of the preceding claims 9 12 and 13 16, wherein the said compound is in the form of a dosage unit.

24. The pharmaceutical composition as described in claim 23, wherein the dosage unit contains 10 to 1500 mg of said compound.

25. The pharmaceutical composition as described in claim 23, wherein said dosage unit is a tablet or capsule.

13. A pharmaceutical composition for the treatment of a hepatitis C virus in a host, comprising an effective amount of a compound of Formula I:

14. A pharmaceutical composition for the treatment of a hepatitis C virus in a host, comprising an effective amount of a compound of Formula IV:

15. A pharmaceutical composition for the treatment of a hepatitis C virus in a host, comprising an effective amount of a compound of Formula III, IV or V, or a pharmaceutically acceptable salt or prodrug thereof, is provided:

16. A pharmaceutical composition for the treatment of a hepatitis C virus in a host, comprising an effective amount of a compound of Formula VI, or a pharmaceutically acceptable salt or prodrug thereof:

26. A compound of Formula I:

27. A compound of Formula II:

28. A pharmaceutical composition for the treatment of a hepatitis C virus in a host, comprising an effective amount of a compound of Formula I:

29. A pharmaceutical composition for the treatment of a hepatitis C virus in a host, comprising an effective amount of a compound of Formula II:

30. A pharmaceutical composition for the treatment of a hepatitis C virus in a host, comprising an effective amount of a compound of Formula I:

31. A pharmaceutical composition for the treatment of a hepatitis C virus in a host, comprising an effective amount of a compound of Formula II: